The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients.
Hai T. Tran
Research Funding - Exelixis
Benjamin L. Legendre
Employment or Leadership Position - Transgenomic
Stock Ownership - Transgenomic
Edward S. Kim
No relevant relationships to disclose
George R. Blumenschein
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Immunogen
Research Funding - Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; MedImmune; Merck; Novartis; Xcovery
Anne S. Tsao
No relevant relationships to disclose
Roy S. Herbst
No relevant relationships to disclose
Ignacio Ivan Wistuba
No relevant relationships to disclose
Marcia Lewis
Consultant or Advisory Role - Transgenomic
Katherine Richardson
Employment or Leadership Position - Transgenomic
Stock Ownership - Transgenomic
Waun Ki Hong
No relevant relationships to disclose
John Heymach
No relevant relationships to disclose